AbbVie, Boehringer Ingelheim in U.S. Settlement on Humira Biosimilar

Date : 05/14/2019 @ 2:53PM
Source : Dow Jones News
Stock : Abbvie Inc. (ABBV)
Quote : 68.54  0.29 (0.42%) @ 1:00AM

AbbVie, Boehringer Ingelheim in U.S. Settlement on Humira Biosimilar

AbbVie Inc. (NYSE:ABBV)
Historical Stock Chart

3 Months : From Apr 2019 to Jul 2019

Click Here for more AbbVie Inc. Charts.

By Colin Kellaher


AbbVie Inc. (ABBV) and Boehringer Ingelheim GmbH on Tuesday said they have resolved their U.S. patent dispute over a biosimilar to Abbvie's Humira, the world's biggest selling drug.

AbbVie said it will grant Boehringer Ingelheim a non-exclusive license to its Humira-related intellectual property in the U.S., allowing the German company to begin selling its Humira biosimilar Cyltezo in the U.S. starting in July 2023.

Biosimilars are near-copies of biologic drugs, such as Humira, that are made from living cells and are analogous to generic copies of traditional pill-form medicines.

Humira, a drug used to treat diseases from rheumatoid arthritis to gut disorders, had nearly $20 billion in global sales in 2018. But AbbVie saw a 5.6% decline in Humira revenue in the first quarter this year, as competition from biosimilars led to a nearly 28% drop in sales overseas.

Sales of Humira biosimilars began in Europe late last year after a key AbbVie European patent expired, but a group of U.S. patents built up by AbbVie has prevented a U.S. launch.

AbbVie sued Boehringer Ingelheim in 2017, alleging that Cyltezo would infringe on many of the Humira patents. Boehringer Ingelheim, a family-owned pharmaceutical company based in Ingelheim, Germany, had accused AbbVie of developing a "patent thicket" to delay competition.

AbbVie, a North Chicago, Ill., biopharmaceutical company, on Tuesday said it will receive royalties from Boehringer Ingelheim, which it said will acknowledge the validity and enforceability of AbbVie's patents as part of the settlement.

Specific terms of the settlement, which involve no payment by AbbVie, weren't disclosed.


-Peter Loftus and Denise Roland contributed to this article.


Write to Colin Kellaher at


(END) Dow Jones Newswires

May 14, 2019 09:38 ET (13:38 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest ABBV Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.